Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents

Journal of Diabetes and its Complications

Volumn 21, Issue 2, 2007, Pages 108-117

  de Dios, Stephanie T ^a,b   Frontanilla, Karen V ^a   Nigro, Julie ^a,b   Ballinger, Mandy L ^a,b   Ivey, Melanie E ^a,b   Cawson, Elizabeth A ^a   Little, Peter J ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

Atherosclerosis; Oral hypoglycemic agents; Proteoglycans; Type 2 diabetes mellitus; Vascular smooth muscle cells

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BIGUANIDE; CETYLPYRIDINIUM SALT; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLYCOSAMINOGLYCAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PHENFORMIN; PIOGLITAZONE; PROTEOGLYCAN; ROSIGLITAZONE; SULFATE; SULFONYLUREA; TOLBUTAMIDE; TRANSFORMING GROWTH FACTOR BETA1; TROGLITAZONE;

ARTICLE; ATHEROGENESIS; BIOSYNTHESIS; BLOOD VESSEL WALL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ELECTROPHORETIC MOBILITY; EVALUATION; GEL MOBILITY SHIFT ASSAY; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; METHODOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRECIPITATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SYNTHESIS; VASCULAR SMOOTH MUSCLE;

ADMINISTRATION, ORAL; ATHEROSCLEROSIS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GLYBURIDE; GLYCOSAMINOGLYCANS; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEINS, LDL; METFORMIN; MUSCLE, SMOOTH, VASCULAR; PHENFORMIN; PROTEIN BINDING; PROTEOGLYCANS; SULFATES; SULFONYLUREA COMPOUNDS; SULFUR RADIOISOTOPES; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33847212846     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2006.03.003     Document Type: Article

References (47)

1. Bailey C.J., and Turner R.C. Metformin. New England Journal of Medicine 334 9 (1996) 574-579
2. Ballinger M., Nigro J., Frontanilla K., Dart A., and Little P. Regulation of glycosaminoglycan structure and atherogenesis. Cellular and Molecular Life Science 61 11 (2004) 1296-1306
3. Betz M.J., Shapiro I., Fassnacht M., Hahner S., Reincke M., and Beuschlein F. Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation. Journal of Clinical Endocrinology 90 7 (2005) 3886-3896
4. Bishop-Bailey D., Hla T., and Warner T.D. Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-gamma ligand therapy. Circulation Research 91 3 (2002) 210-217
5. Camejo G. The interaction of lipids and lipoproteins with the intercellular matrix of arterial tissue: its possible role in atherogenesis. Advances in Lipid Research 19 (1982) 1-53
6. Camejo G., Olsson U., Hurt-Camejo E., Baharamian N., and Bondjers G. The extracellular matrix on atherogenesis and diabetes-associated vascular disease. Atherosclerosis Supplements 3 1 (2002) 3-9
7. Chen Z., Ishibashi S., Perrey S., Osuga J., Gotoda T., Kitamine T., Tamura Y., Okazaki H., Yahagi N., Iizuka Y., Shionoiri F., Ohashi K., Harada K., Shimano H., Nagai R., and Yamada N. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arteriosclerosis, Thrombosis, and Vascular Biology 21 3 (2001) 372-377
8. Claudel T., Leibowitz M.D., Fievet C., Tailleux A., Wagner B., Repa J.J., Torpier G., Lobaccaro J.M., Paterniti J.R., Mangelsdorf D.J., Heyman R.A., and Auwerx J. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proceedings of the National Academy of Sciences of the United States of America 98 5 (2001) 2610-2615
9. Collins A.R., Meehan W.P., Kintscher U., Jackson S., Wakino S., Noh G., Palinski W., Hsueh W.A., and Law R.E. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and non-diabetic low density lipoprotein receptor-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology 21 3 (2001) 365-371
10. Consoli A., and Devangelio E. Thiazolidinediones and inflammation. Lupus 14 9 (2005) 794-797
11. Dandona P., and Aljada A. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. American Journal of Cardiology 90 5A (2002) 27G-33G
12. DCCT. The absence of a glycemic threshold for the development of long-term complications: the perspective of the diabetes control and complications trial. Diabetes 45 (1996) 1289-1298
13. de Dios S.T., Bruemmer D., Dilley R.J., Ivey M.E., Jennings G.L., Law R.E., and Little P.J. Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 107 20 (2003) 2548-2550
14. de Dios S.T., Hannan K.M., Dilley R.J., Hill M.A., and Little P.J. Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells. Journal of Diabetes and its Complications 15 3 (2001) 120-127
15. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefebvre P.J., Murray G.D., Standl E., Wilcox R.G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R.J., Koranyi L., Laakso M., Mokan M., Norkus A., Pirags V., Podar T., Scheen A., Scherbaum W., Schernthaner G., Schmitz O., Skrha J., Smith U., and Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 9493 (2005) 1279-1289
16. Gotto Jr. A.M., and Farmer J.A. Pleiotropic effects of statins: do they matter?. Current Opinion in Lipidology 12 4 (2001) 391-394
17. Haffner S.J., and Cassells H. Hyperglycemia as a cardiovascular risk factor. American Journal of Medicine 115 Suppl 8A (2003) 6S-11S
18. Haffner S.M., D'Agostino Jr. R., Mykkanen L., Tracy R., Howard B., Rewers M., Selby J., Savage P.J., and Saad M.F. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 22 4 (1999) 562-568
19. Hannan K.M., Dilley R.J., De Dios S.T., and Little P.J. Troglitazone stimulates repair of the endothelium and inhibits neointimal formation in denuded rat aorta. Arteriosclerosis, Thrombosis, and Vascular Biology 23 5 (2003) 762-768
20. Hayashi J.N., Ito H., Kanayasu T., Asuwa N., Morita I., Ishii T., and Murota S.-I. Effects of glucose on migration, proliferation and tube formation by vascular endothelial cells. Virchows Archive B Cell Pathology 60 (1991) 245-252
21. Higa M., Zhou Y.T., Ravazzola M., Baetens D., Orci L., and Unger R.H. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proceedings of the National Academy of Sciences of the United States of America 96 20 (1999) 11513-11518
22. Hsueh W.A., Jackson S., and Law R.E. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care 24 2 (2001) 392-397
23. Hsueh W.A., and Law R.E. PPARgamma and atherosclerosis: effects on cell growth and movement. Arteriosclerosis, Thrombosis, and Vascular Biology 21 12 (2001) 1891-1895
24. Iozzo R.V. Matrix proteoglycans: from molecular design to cellular function. Annual Review of Biochemistry 67 (1998) 609-652
25. Jaakkola T., Backman J.T., Neuvonen M., Laitila J., and Neuvonen P.J. Effect if rifampicin on the pharmacokinetics of pioglitazone. British Journal of Clinical Pharmacology 61 1 (2005) 70-78
26. Jensen T. The HOPE study and diabetes. Heart Outcomes Prevention Evaluation. Lancet 355 9210 (2000) 1181-1182
27. Langenfeld M.R., Forst T., Hohberg C., Kann P., Lubben G., Konrad T., Fullert S.D., Sachara C., and Pfutzner A. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 111 19 (2005) 2525-2531
28. Law R.E., Meehan W.P., Xi X.P., Graf K., Wuthrich D.A., Coats W., Faxon D., and Hsueh W.A. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. Journal of Clinical Investigation 98 8 (1996) 1897-1905
29. Li A.C., Brown K.K., Silvestre M.J., Willson T.M., Palinski W., and Glass C.K. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. Journal of Clinical Investigation 106 4 (2000) 523-531
30. Little P.J., Tannock L., Olin K.L., Chait A., and Wight T.N. Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-beta1 exhibit increased binding to LDLs. Arteriosclerosis, Thrombosis, and Vascular Biology 22 1 (2002) 55-60
31. Liu J., Lu H., Huang R., Lin D., Wu X., Lin Q., Zheng J., Pan X., Peng J., Song Y., Zhang M., Hou M., and Chen F. Peroxisome proliferator activated receptor-gamma ligands induced cell growth inhibition and its influence on matrix metalloproteinase activity in human myeloid leukemia cells. Cancer Chemotherapy and Pharmacology 56 4 (2005) 400-408
32. Nattrass M., Sizer K., and Alberti K.G. Correlation of plasma phenformin concentration with metabolic effects in normal subjects. Clinical Science (London) 58 2 (1980) 153-155
33. Nigro J., Dilley R.J., and Little P.J. Differential effects of gemfibrozil on migration, proliferation and proteoglycan production in human vascular smooth muscle cells. Atherosclerosis 162 1 (2002) 119-129
34. Nigro J., Ballinger M.L., Dilley R.J., Jennings G.L., Wight T.N., and Little P.J. Fenofibrate modifies human vascular smooth muscle proteoglycans and reduces lipoprotein binding. Diabetologia 47 12 (2004) 2105-2113
35. Peuler J.D., Phare S.M., Iannucci A.R., and Hodorek M.J. Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation. American Journal of Hypertension 9 2 (1996) 188-192
36. Prydz K., and Dalen K.T. Synthesis and sorting of proteoglycans. Journal of Cell Science 113 Pt 2 (2000) 193-205
37. Reusch J.E. Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome. The American Journal of Cardiology 90 5A (2002) 19G-26G
38. Schonherr E., Jarvelainen H.T., Kinsella M.G., Sandell L.J., and Wight T.N. Platelet-derived growth factor and transforming growth factor-beta 1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells. Arteriosclerosis Thrombosis 13 7 (1993) 1026-1036
39. Sidhu J.S., Kaposzta Z., Markus H.S., and Kaski J.C. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arteriosclerosis, Thrombosis, and VascularBiology 24 5 (2004) 930-934
40. Tannock L.R., Little P.J., Tsoi C., Barrett P.H.R., Wight T.N., and Chait A. Thiazolidinediones reduce the LDL binding affinity of non-human primate vascular cell proteoglycans. Diabetologia 47 5 (2004) 837-843
41. Thompson-Culkin K., Zussman B., Miller A.K., and Freed M.I. Pharmacokinetics of rosiglitazone in patients with end-stage renal disease. The Journal of International Medical Research 30 4 (2002) 391-399
42. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
43. Umland E.M., and Romanelli A.M. Cardiovascular effects of troglitazone. The Annals of Pharmacotherapy 33 2 (1999) 229-232
44. Wakino S., Kintscher U., Kim S., Yin F., Hsueh W.A., and Law R.E. Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1→S transition in vascular smooth muscle cells. The Journal of Biological Chemistry 275 29 (2000) 22435-22441
45. Weissman P. Reappraisal of the pharmacologic approach to treatment of type 2 diabetes mellitus. The American Journal of Cardiology 90 5A (2002) 42G-50G
46. Williams K.J., and Tabas I. The response-to-retention hypothesis of early atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology 15 5 (1995) 551-561
47. Young M.A., Eckland D.J., Eastmond R., and Lettis S. Establishing the dose response curve for metabolic control with troglitazone, an insulin action enhancer, in type 2 diabetes patients. Annals of Medicine 30 2 (1998) 206-212